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Background: Podoplanin is a type I transmembrane sialomucin-like glycoprotein that is specifically expressed in 
lymphatic endothelial cells. Studies have shown that assessment of podoplanin expression in the epithelial cells 
can be used to predict the malignant transformation of potentially malignant disorders and the metastatic tendency 
of primary head and neck squamous cell carcinoma. The aim of our study was to compare the expression of podo-
planin in oral leukoplakia, oral submucous fibrosis and oral squamous cell carcinoma with that in normal buccal 
mucosa by immunohistochemical methods. 
Materials and Methods: Immunohistochemical expression of podoplanin was analyzed in 20 cases each of oral 
leukoplakia, oral submucous fibrosis, oral squamous cell carcinoma and normal buccal mucosa, with monoclonal 
antibody D2-40. The expression of podoplanin was graded from  grade 0-4. 
Results: There was a statistically significant upregulation of the grades of podoplanin expression in oral squamous 
cell carcinoma(100%), oral submucous fibrosis (90%) and oral leukoplakia (65%) when compared to that in normal 
mucosa(35%). Podoplanin expression increased with decrease in grades of differentiation in oral squamous cell carci-
noma . Podoplanin expression in the samples of oral submucous fibrosis was higher than that in oral leukoplakia. 
Conclusions: Evaluation of podoplanin expression in the epithelial cells of oral dysplastic lesions may provide 
valuable information to predict their risk of malignant transformation.





Oral cancer is a predominant cause of cancer death, 
and oral squamous cell carcinoma (OSCC) accounts for 
more than 90% of all oral cancers (1). Early detection of 
potentially malignant disorders can decrease the morbi-
dity and mortality associated with oral cancer. Currently, 
histologic assessment of epithelial dysplasia is the gold 
standard for determining the malignant transformation 
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risk of oral leukoplakia. �ut, the accuracy of the histopa-
thologic assessment of epithelial dysplasia depends on 
the quality of the tissue and the site at which a biopsy 
is taken. It also carries the risk of interobserver and in-
traobserver variability (2). The traditional grading sys-
tem of oral epithelial dysplasia into mild, moderate and 
severe dysplasia does not permit accurate prediction of 
which cases may eventually develop into malignancy 
(3). Many investigators have remarked that potentia-
lly malignant disorders with epithelial dysplasia have 
shown to develop into cancer more readily than those 
without dysplasia (4,5). In contrast, all epithelial dys-
plasias do not develop into cancer and some have shown 
to regress with time (6,7). Oral cancer may also develop 
from lesions that lack dysplastic features (8).
Lack of objectivity in the histologic criteria such as the 
arbitrary division of gradings and difficulties in predic-
ting the outcome of individual cases demanded the ur-
gent identification of more reliable markers (9). One such 
marker is podoplanin which is widely used as a specific 
marker for lymphatic endothelial cells and lymphangio-
genesis.  Podoplanin is expressed on lymphatic but not 
on blood vessel endothelium (10).
Human podoplanin is a type I transmembrane sialomu-
cin-like glycoprotein consisting of 162 amino acids. It is 
expressed in a wide variety of normal as well as tumor 
cells. In normal human tissue, podoplanin is expressed 
in kidney podocytes, skeletal muscle, placenta, lung, 
heart, myofibroblasts of the breast and salivary glands, 
osteoblasts and mesothelial cells. Podoplanin plays a 
significant role in preventing cellular adhesion and is 
involved in the regulation of the shape of podocyte foot 
processes and in the maintenance of glomerular per-
meability (10,11).
Various types of tumor cells also express podoplanin 
such as vascular tumors, central nervous system, germ 
cell tumors and squamous cell carcinoma. Podoplanin 
might favour tumor invasion through its ability to re-
model actin in the cytoskeleton of tumor cells, resulting 
in increased motility. The association between podopla-
nin and the actin cytoskeleton seems to be mediated by 
ezrin, which is markedly phosphorylated in the presence 
of podoplanin overexpression. Podoplanin expression 
increases the activities of Rho GTPases, mainly Rho A, 
which might indicate a change in the cytoskeletal orga-
nization of the cells (12). Wicki and Christofori showed 
that invasion of podoplanin- expressing tumor cells was 
correlated with an overexpression of matrix metallopro-
teinases (MMPs) and it could be inhibited by specific 
inhibitors of MMPs (10).
In the past, podoplanin had been used often to assess 
intratumoral and peritumoral lymphovascular density 
in oral squamous cell carcinoma, which was correlated 
with metastatic spread to the lymph nodes and a poor 
prognosis (13-15). Studies have proven that podopla-
nin is also expressed in the epithelial cells of oral dys-
plastic and hyperplastic lesions with a risk of cancer 
development(8,16-21).
The purpose of our study was to compare the imunohis-
tochemical expression of podoplanin in oral leukopla-




Formalin fixed paraffin embedded blocks were obtai-
ned from the archives of Department of Oral and Maxi-
llofacial Pathology. Twenty cases each of leukoplakia, 
OSF and OSCC in the age group of 20-70 years were 
included in the study. Fresh H& E stained sections were 
prepared from the archived blocks of leukoplakia, OSF 
and OSCC. Tissue sections without epithelium and tis-
sues from non-oropharyngeal sites were excluded. Each 
section was re-examined by a single qualified oral pa-
thologist to confirm the histopathological diagnosis. 
Cases of leukoplakia were graded by the WHO criteria 
for dysplasia, OSF by classification of Pindborg JJ and 
Sirsat SM and OSCC by Broder’s classification(22,23). 
Control group consisted of twenty samples of normal 
non- inflamed buccal mucosa obtained during removal 
of impacted third molar. Demographic and clinical data 
of the patients are shown in table 1. The study was re-
viewed and approved by the Institutional Ethical Com-
mittee. Written informed consent was obtained from all 
patients.
-Immunohistochemistry procedure
Four micrometer thick sections from formalin fixed, pa-
raffin embedded tissue blocks were mounted on posi-
tively charged 3-amino propyl triethoxy silane (APES) 
coated glass slides. Slides were deparaffinized  in xyle-
ne and rehydrated through  decreasig concentrations  of 
ethanol. For antigen retrieval, slides were heated in a 
pressure cooker in TRIS- EDTA buffer for 5 minutes. 
Endogenous peroxidase activity was blocked with 3% 
hydrogen peroxide for 10 minutes and the slides were 
treated with Ultra violet block reagent for 5 minutes. 
Slides were incubated with mouse monoclonal antihu-
man podoplanin primary antibody (D2-40) (Dakocyto-
mation, California Inc. USA) at room temperature for 
1 hour, followed by secondary antibo dy horse radish 
peroxidase (Dakocytomation, California Inc. USA) for 
30 minutes. Staining was visualised with 3’ –Diamin-
obenzidine Tetrahydrochloride - a substrate chromogen 
(Dakocytomation, California Inc. USA) and counter 
stained with Harris hematoxylin. Sections were then 
dehydrated, cleared, mounted and observed under light 
microscope.
-Evaluation
Podoplanin expression was graded according to the pro-
cedure done by Inoue et al. (8). The score was based on 
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Clinical characteristics Leukoplakia OSF OSCC Normal
Gender
Male 14 (70%) 18 (90%) 14(70%) 12(60%)
Female 6 (30%) 2(10%) 6(30%) 8(40%)
Age 56.7 ± 8.2 49.5 ±13.5 53.9 ±10.9 34.3 ±9.5
Smoking
Yes 10(50%) 17(85%) 15 (75%) 1 (5%)
No 10(50%) 3(15%) 5 (25%) 19 (95%)
Alcohol
Yes 13 (65%) 8 (40%) 11(55%) 1 (5%)
No 7 (35%) 12(60%) 9(45%) 19 (95%)
Site of the lesion
�uccal mucosa 10 20 5 20
Tongue 6 - 5 -
Gingiva 1 - 5 -
Retromolar area 2 - 1 -
Soft palate 1 - 1 -
Floor of the mouth - - 2 -
Lower lip - - 1 -
Table 1: Demographic and clinical data.
the examination of the whole section by three oral pa-
thologists who were blinded to the clinical information, 
using a multi headed microscope. Expression of podo-
planin in the lymphatic endothelial cells in the connecti-
ve tissue served as the positive control.
Grading of podoplanin expression 
Expression of podoplanin was predominantly membra-
nous. Expression was graded as;
0- If no expression is observed in any part of the epi-
thelium
1- If intensity of expression is weaker than that in 
lymphatic vessels and observed in the basal layer of epi-
thelium.
2- If intensity of expression is weaker than that in 
lymphatic vessels and observed in more than two layers 
of epithelium.
3- If intensity of expression is equal to that in lymphatic 
vessels and observed in the basal layer of epithelium.
4- If intensity of expression is equal to that in lymphatic 
vessels and observed in more than two layers of epithe-
lium.
-Statistical analysis:
Data was analyzed using computer software, Statisti-
cal Package for Social Sciences (SPSS) version 16 for 
Windows Operating System using Kruskal-Wallis and 
Mann-Whitney tests. The association between podopla-
nin expression status and clinicopathologic parameters 
were analyzed using the chi- squared test. A multivariate 
analysis was done using clinical data, histopathologic 
data, and podoplanin expression as cofactors to evaluate 
if podoplanin is an independent cofactor for cancer de-
velopment.  
Results
-Podoplanin expression and clinicopathologic characte-
ristics
Among the 20 cases of oral leukoplakia, 14 were males 
and 6 were females. The mean age of the patients was 
56.7 ± 8.2 years. Most frequently affected sites were 
buccal mucosa (10 cases), followed by tongue (6 cases). 
Of the 20 cases of OSF, 18 were males and 2 were fe-
males. The average age of the patients was 49.5 ± 13.5 
years. Out of the 20 cases of OSCC, 14 were males and 6 
were females. �uccal mucosa, gingiva and lateral border 
of tongue were most commonly affected (5 cases each). 
Average age of the patients was 53.9 ± 10.9 years. There 
was no statistically significant correlation between po-
doplanin expression and age, gender or site of the lesion 
in any of  the groups.
-Podoplanin expression in oral leukoplakia, OSF, OSCC 
and normal buccal mucosa
Among the 20 cases of oral leukoplakia, 13 cases (65%) 
showed a positive expression of podoplanin in the epi-
thelium, whereas 7 cases (35%) were negative. Among 
the 20 cases of OSF, 18 cases (90%) had positive ex-
pression of podoplanin; 2 cases (10%) showed grade 0. 
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Among OSCC, all cases showed positive podoplanin 
expression. Among the 20 samples of normal mucosa, 
13 (65%) were negative for podoplanin. Seven tissues 
(35%) showed positive podoplanin expression focally 
in small groups of cells in the basal layer of epithelium 
(grade 1). Podoplanin expression in oral leukoplakia and 
Fig. 1: Leukoplakia showing  podoplanin expression  A) grade 1, �) grade 2,  C) grade 4  (x40)  Oral squamous cell carcinoma showing 
podoplanin expression D) grade 2, E) grade 3,  F) grade 4  (x40).
OSCC are shown in figure 1 whereas expression in OSF 
is given in figure 2. Graphical representation of podopla-
nin expression in normal mucosa, OSF, different histo-
pathological grades of oral leukoplakia and OSCC are 
shown in figure 3. 
Comparison of grades of podoplanin expression among 
Fig. 2: Oral submucous fibrosis showing  podoplanin expression A) grade 1 B) grade 2, C) grade 3, D)grade 
4  (x40).
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Fig. 3: Graph showing the association between histologic grading and podoplanin expression.
oral leukoplakia, OSF and OSCC with  that in normal 
mucosa using Kruskal-Wallis test showed that the va-
riation in the grades of podoplanin expression among 
groups was significant at 0.000 level (Table 2). Pair wise 
comparison of podoplanin  expression using Mann-
Whitney test showed that the grades of podoplanin 
expression is significantly high among OSCC (Z=5.4, 
p<0.01) and OSF (Z=3.69, p<0.01) when compared to 
that in normal oral mucosa. The associations between 
podoplanin expression status and clinicopathologic pa-
rameters were analyzed using the chi- squared test for 
categoric variables. When the multivariate analysis was 
done, a  highly significant association (p< 0.001) was 
seen between  podoplanin expression and grade of diffe-
rentiation in normal mucosa versus  OSCC.
Discussion
Podoplanin expression was frequently used for evalua-
ting the lymphovascular density in head and neck squa-
mous cell carcinoma(13,14). Yuan et al. first observed 
podoplanin expression in the basal cell layers in some 
of the hyperplastic and dysplastic epithelial areas ad-
jacent to tumors (17). Kawaguchi et al. concluded that 
podoplanin expression extending to suprabasal layers in 
the epithelia of oral PMDs may represent upward clonal 
expansion of stem cells during carcinogenesis; and oral 
premalignancy with such clonal expansion may imply 
significantly higher risk of malignant transformation 
(16). Studies conducted by Inoue et al., Funayama et al., 
and de Vincent et al. also showed podoplanin expression 
in dysplastic cells of PMDs (8,18,21).
In the present  study, we analyzed the immunohisto-
chemical expression of podoplanin in 20 cases each of 
oral leukoplakia, OSF, OSCC and normal mucosa, and 
correlated it with clinicopathological parameters. Posi-
tive expression of podoplanin was observed in 65% of 
leukoplakia cases whereas 90% of OSF cases were po-
doplanin positive. Among OSCC, all cases showed posi-
tive podoplanin expression. Focal podoplanin positivity 
(grade 1) was expressed by 35% of normal mucosa. A 
statistically significant increase in podoplanin expres-
sion was observed in OSCC (Z=5.4, p<0.01) and OSF 
(Z=3.69, p<0.01) when compared to that in normal oral 
mucosa. 
Kawaguchi et al., Funayama et al., Inoue et al. , Kre-
ppel et al., de Vincent et al. and Patil et al. showed that 
intensity of podoplanin expression increased with the 
severity of dysplasia and suggested it as a useful pre-
dictor for the risk of cancer development in oral PMDs 
(8,16,18,20,21,24).  In our study, podoplanin positivity 
was observed in 65% cases of leukoplakia, which was 
nearly similar to that of Funayama et al. As most of our 
samples were mild dysplasia (85%), we could not get 
a statistically significant correlation between severity of 
dysplasia and podoplanin expression. 
Kawaguchi et al. observed that 37% of oral cancers de-
veloped in patients with podoplanin negative PMDs. 
They suggested that these podoplanin negative lesions 
in the study might have been biopsied before the abnor-
mality developed or  the biopsies might have been taken 
from a different clonal site other than the one in which 
cancer eventually developed (16). These factors may be 
attributed for the negative podoplanin expression in our 
study also.
Speight et al. have reported a higher malignant transfor-
mation rate of OSF than leukoplakia (25). In our study, 
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among the 20 cases of OSF, 18 cases had positive ex-
pression of podoplanin; one was grade 4 and eight cases 
show ed grade 3. The expression of podoplanin in OSF 
was 90%; which was much higher than that in leukopla-
kia (65%), probably suggesting its increased risk of ma-
lignant transformation. However, these results remain 
inconclusive as our sample size was small and long term 
follow up was not done. Out of the 20 cases of OSF, 4 
were early stage and 16 were advanced stage. We could 
not find any correlation between the podoplanin expres-
sion and the histological stages of OSF.
Various studies have shown high podoplanin positivity 
in OSCC, [Prasad � et al. (90%), Inoue et al. (95.7%), 
Kreppel et al. (84%) and Funayama et al. (100%)]
(8,18,26,27). A statistically significant association bet-
ween podoplanin expression and grades of differentia-
tion was observed by Inoue et al. whose grading crite-
ria we followed. Similar statistical correlation was also 
shown by Parasad et al. and Patil et al. (24,26). In our 
study, 12.5% of the well differentiated OSCC, showed 
grade 4; whereas 41.5% of moderately differentiated 
OSCC were grade 4. None of the cases showed grade 0 
or grade 1. Even though the results were not statistically 
significant, an increasing expression of podoplanin with 
decreasing grades of differentiation was observed. 
In our study, 35% samples showed positive podoplanin 
expression focally in small groups of cells in the basal la-
yer of epithelium, which was similar to the observations 
by de Vincente et al. (21). Schacht et al. have reported 
focal expression of podoplanin in the basal keratinocytes 
of skin, cervix and esophagus (28). Contrary to these re-
sults, negative podoplanin expression was reported in 
oral  epithelium by  Funayama et al., and Margaritescu 
et al. (8,29). Miyasaki et al. found positive  podoplanin 
expression in the basal cells of inflamed gingival epithe-
lium (30).
Inoue et al. have shown that increase in the podoplanin 
expression is associated with the development of dys-
plasia- carcinoma sequence in the oral cavity (8). In our 
study also, there was a statistically significant variation 
in the grades of podoplanin expression in OSCC (100%), 
OSF (90%) and oral leukoplakia (65%) when compared 
to that in normal mucosa (35%).
Conclusions
At present, severity of epithelial dysplasia is the most 
important indicator for determining the risk of develop-
ment of oral cancer in PMDs. Since the interpretation of 
podoplanin expression is relatively simple, it may also 
be included along with the standard histopathological 
examination of the dysplastic lesions.
A limitation of the present study is the small sample size. 
Further studies with larger sample size and follow up 
may elucidate the exact role of biomarkers like podopla-
nin in PMDs and invasive carcinoma. 
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